ABSTRACT

Introduction

There are more than two dozen bispecific antibodies (BsAbs) in development with a variety of designs which are relevant to breast cancer. The field of BsAbs for breast cancer includes agents that co-direct immune recognition of the cancer cell, target unique cancer antigens, and target the microenvironment. BsAbs are being developed for use as antibody-drug conjugates and as homing signals for engineered T-cells.

Areas covered

This review covers potential targets for bispecific antibodies, agents in pre-clinical development, agents in clinical trials, combinatorial therapies, and future directions.

Expert opinion

There is no BsAb approval expected for breast cancer in the near term, but late-stage trials are underway. Future BsAb roles in breast cancer are possible given unmet needs in estrogen receptor+ disease, residual disease, and de-escalating chemotherapy use. The HER2+ space shows hints of success for BsAbs, but is already crowded. Areas of unmet need still exist.

中文翻译：

---

用于治疗乳腺癌的双特异性抗体

摘要

介绍

目前有超过两打双特异性抗体 (BsAb) 正在开发中，其设计多种多样，与乳腺癌相关。乳腺癌双特异性抗体领域包括共同指导癌细胞免疫识别、靶向独特癌症抗原和靶向微环境的药物。BsAb 正在开发用作抗体-药物缀合物和工程化 T 细胞的归巢信号。

覆盖领域

这篇综述涵盖了双特异性抗体的潜在靶标、临床前开发药物、临床试验药物、组合疗法和未来方向。

专家意见

预计短期内不会批准用于乳腺癌的双特异性抗体，但后期试验正在进行中。鉴于雌激素受体+疾病、残留疾病和化疗使用逐步减少等方面的需求未得到满足，未来 BsAb 在乳腺癌中的作用是可能的。HER2+ 空间显示出 BsAb 成功的迹象，但已经很拥挤了。需求未得到满足的领域仍然存在。